semaglutide diabetes trial may reduce Alzheimer's risk in diabetics Semaglutide could be 'practice changing'

Urbina PhD 2 , Flor Lpez MSc 2 , Frank Hernndez Rosales PhD 1 1 Ozone Research Center, National Center for Scientific Research

Freeze-dried (lyophilized) porous white solid

In the consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE), GLP-1 RA is recommended as monotherapy in individuals with HbA1c 1% and weight reduction 3% e Compared to placebo f Compared to other incretin mimetics g Compared to exenatide and liraglutide h Compared to other therapies i Compared to comparator drugs j Compared to exenatide formulations and albiglutide Body Weight and Composition GLP-1 RA decreases gastrointestinal motility and hence increases the time for nutrient absorption

Those who do not experience the intended results would not be a good candidate to continue the medication